{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:53:59Z","timestamp":1788292439987,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,15]]},"DOI":"10.2146\/ajhp100348","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T19:07:01Z","timestamp":1312484821000},"page":"1506-1519","source":"Crossref","is-referenced-by-count":49,"title":["Dabigatran etexilate: A novel oral direct thrombin inhibitor"],"prefix":"10.1093","volume":"68","author":[{"given":"Matthew L.","family":"Blommel","sequence":"first","affiliation":[{"name":"West Virginia Center for Drug and Health Information, Morgantown, and Assistant Clinical Professor, Department of Clinical Pharmacy, School of Pharmacy, West Virginia University, Morgantown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Blommel","sequence":"additional","affiliation":[{"name":"Monongahela Valley Hospital, Monongahela, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106020741000_b1-0681506","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","article-title":"Incidence of venous thromboembolism: a community-based study in Western France","volume":"83","author":"Oger","year":"2000","journal-title":"Thromb Haemost."},{"key":"key\n\t\t\t\t2019041106020741000_b2-0681506","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1525-1497.2006.00458.x","article-title":"The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism","volume":"21","author":"Spencer","year":"2006","journal-title":"J Gen Intern Med."},{"key":"key\n\t\t\t\t2019041106020741000_b3-0681506","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.158.19.2093","article-title":"Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation","volume":"158","author":"Brass","year":"1998","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106020741000_b4-0681506","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041106020741000_b5-0681506","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106020741000_b6-0681506","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"The ACTIVE Writing Group on behalf of the ACTIVE Investigators","year":"2006","journal-title":"Lancet."},{"issue":"(suppl)","key":"key\n\t\t\t\t2019041106020741000_b7-0681506","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest."},{"key":"key\n\t\t\t\t2019041106020741000_b8-0681506","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1592\/phco.30.4.330","article-title":"Comparison of two different models of anticoagulation services with usual medical care","volume":"30","author":"Rudd","year":"2010","journal-title":"Pharmacotherapy."},{"key":"key\n\t\t\t\t2019041106020741000_b9-0681506","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/archinte.158.18.2001","article-title":"Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin","volume":"158","author":"Harrison","year":"1998","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106020741000_b10-0681506","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2106\/00004623-200704000-00018","article-title":"The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty","volume":"89","author":"Skedgal","year":"2007","journal-title":"J Bone Joint Surg Am."},{"key":"key\n\t\t\t\t2019041106020741000_b11-0681506","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1524-4733.1999.24003.x","article-title":"Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement","volume":"2","author":"Bergquist","year":"1999","journal-title":"Value Health."},{"key":"key\n\t\t\t\t2019041106020741000_b12-0681506","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2146\/ajhp040534","article-title":"Ximelagatran: an orally active direct thrombin inhibitor","volume":"62","author":"Gulseth","year":"2005","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019041106020741000_b13-0681506","volume-title":"Pradaxa (dabigatran etexilate) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106020741000_b14-0681506","unstructured":"Boehringer Ingelheim. Dabigatran etexilate recommended for approval in atrial fibrillation for stroke prevention in Europe. www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2011\/15_april_2011_dabigatran.html (accessed 2011 Apr 18)."},{"key":"key\n\t\t\t\t2019041106020741000_b15-0681506","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"key\n\t\t\t\t2019041106020741000_b16-0681506","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"key\n\t\t\t\t2019041106020741000_b17-0681506","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhitibors","volume":"45","author":"Hauel","year":"2002","journal-title":"J Med Chem."},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041106020741000_b18-0681506","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1538-7836.2007.02552.x","article-title":"Factor Xa or thrombin: is thrombin a better target?","volume":"5","author":"Weitz","year":"2007","journal-title":"J Thromb Hemost."},{"key":"key\n\t\t\t\t2019041106020741000_b19-0681506","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1592\/phco.28.11.1354","article-title":"Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases","volume":"28","author":"Baetz","year":"2008","journal-title":"Pharmacotherapy."},{"key":"key\n\t\t\t\t2019041106020741000_b20-0681506","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos."},{"key":"key\n\t\t\t\t2019041106020741000_b21-0681506","unstructured":"Boehringer Ingelheim International GmbH. Pradaxa: summary of product characteristics. www.pradaxa.com\/HCP\/Home\/prescribing_information\/index.jsp (accessed 2010 May 20)."},{"key":"key\n\t\t\t\t2019041106020741000_b22-0681506","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The new oral anticoagulants","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood."},{"key":"key\n\t\t\t\t2019041106020741000_b23-0681506","first-page":"173","article-title":"Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate","volume":"3","author":"Bellamy","year":"2009","journal-title":"Patient Prefer Adherence."},{"key":"key\n\t\t\t\t2019041106020741000_b24-0681506","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"key\n\t\t\t\t2019041106020741000_b25-0681506","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"key\n\t\t\t\t2019041106020741000_b26-0681506","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"key\n\t\t\t\t2019041106020741000_b27-0681506","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106020741000_b28-0681506","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulation control","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106020741000_b29-0681506","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMe0906886","article-title":"Can we rely on RE-LY","volume":"361","author":"Gage","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041106020741000_b30-0681506","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost."},{"key":"key\n\t\t\t\t2019041106020741000_b31-0681506","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106020741000_b32-0681506","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost."},{"key":"key\n\t\t\t\t2019041106020741000_b33-0681506","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty."},{"key":"key\n\t\t\t\t2019041106020741000_b34-0681506","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106020741000_b35-0681506","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low molecular weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA."},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041106020741000_b36-0681506","first-page":"P1612","article-title":"Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects","volume":"3","author":"Stangier","year":"2005","journal-title":"J Thromb Haemost."},{"key":"key\n\t\t\t\t2019041106020741000_b37-0681506","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1634\/theoncologist.12-8-927","article-title":"Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein)","volume":"12","author":"Marchetti","year":"2007","journal-title":"Oncologist."},{"key":"key\n\t\t\t\t2019041106020741000_b38-0681506","first-page":"253","article-title":"Drug metabolism","volume-title":"Foye\u2019s principles of medicinal chemistry","author":"Williams","year":"2008","edition":"6th ed"},{"key":"key\n\t\t\t\t2019041106020741000_b39-0681506","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/ci050041k","article-title":"Classification of substrates and inhibitors of p-glycoprotein using unsupervised machine learning approach","volume":"45","author":"Wang","year":"2005","journal-title":"J Chem Inf Model."},{"key":"key\n\t\t\t\t2019041106020741000_b40-0681506","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106020741000_b41-0681506","unstructured":"Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm249005.htm (accessed 2011 Apr 19)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/16\/1506\/28349877\/ajhp1506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T01:35:56Z","timestamp":1592789756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/16\/1506\/5129243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,15]]},"references-count":41,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,8,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100348","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,8,15]]},"published":{"date-parts":[[2011,8,15]]}}}